The  ||| S:0 E:4 ||| DT
food  ||| S:4 E:9 ||| NN
born  ||| S:9 E:14 ||| VBN
mycotoxin  ||| S:14 E:24 ||| JJ
deoxynivalenol  ||| S:24 E:39 ||| NN
induces  ||| S:39 E:47 ||| VBZ
low-grade  ||| S:47 E:57 ||| JJ
inflammation  ||| S:57 E:70 ||| NN
in  ||| S:70 E:73 ||| IN
mice  ||| S:73 E:78 ||| NNS
in  ||| S:78 E:81 ||| IN
the  ||| S:81 E:85 ||| DT
absence  ||| S:85 E:93 ||| NN
of  ||| S:93 E:96 ||| IN
observed-adverse  ||| S:96 E:113 ||| JJ
effects  ||| S:113 E:121 ||| NNS
Deoxynivalenol  ||| S:121 E:136 ||| NNP
( ||| S:136 E:137 ||| -LRB-
DON ||| S:137 E:140 ||| NNP
)  ||| S:140 E:142 ||| -RRB-
is  ||| S:142 E:145 ||| VBZ
the  ||| S:145 E:149 ||| DT
most  ||| S:149 E:154 ||| RBS
common  ||| S:154 E:161 ||| JJ
fungi  ||| S:161 E:167 ||| JJ
toxin  ||| S:167 E:173 ||| NN
contaminating  ||| S:173 E:187 ||| NN
cereals  ||| S:187 E:195 ||| NNS
and  ||| S:195 E:199 ||| CC
cereal-derived  ||| S:199 E:214 ||| JJ
products ||| S:214 E:222 ||| NNS
.  ||| S:222 E:224 ||| .
High  ||| S:224 E:229 ||| JJ
consumption  ||| S:229 E:241 ||| NN
of  ||| S:241 E:244 ||| IN
DON  ||| S:244 E:248 ||| NNP
is  ||| S:248 E:251 ||| VBZ
implicated  ||| S:251 E:262 ||| VBN
in  ||| S:262 E:265 ||| IN
mycotoxicoses  ||| S:265 E:279 ||| NN
and  ||| S:279 E:283 ||| CC
causes  ||| S:283 E:290 ||| VBZ
a  ||| S:290 E:292 ||| DT
set  ||| S:292 E:296 ||| NN
of  ||| S:296 E:299 ||| IN
symptoms  ||| S:299 E:308 ||| NNS
including  ||| S:308 E:318 ||| VBG
diarrhea ||| S:318 E:326 ||| NN
,  ||| S:326 E:328 ||| ,
vomiting ||| S:328 E:336 ||| NN
,  ||| S:336 E:338 ||| ,
reduced  ||| S:338 E:346 ||| VBN
weight  ||| S:346 E:353 ||| NN
gain  ||| S:353 E:358 ||| NN
or  ||| S:358 E:361 ||| CC
immunologic  ||| S:361 E:373 ||| JJ
effects ||| S:373 E:380 ||| NNS
.  ||| S:380 E:382 ||| .
However ||| S:382 E:389 ||| RB
,  ||| S:389 E:391 ||| ,
such  ||| S:391 E:396 ||| JJ
clinical  ||| S:396 E:405 ||| JJ
intoxications  ||| S:405 E:419 ||| NNS
are  ||| S:419 E:423 ||| VBP
rare  ||| S:423 E:428 ||| JJ
in  ||| S:428 E:431 ||| IN
humans ||| S:431 E:437 ||| NNS
,  ||| S:437 E:439 ||| ,
who  ||| S:439 E:443 ||| WP
are  ||| S:443 E:447 ||| VBP
most  ||| S:447 E:452 ||| RBS
frequently ||| S:452 E:462 ||| RB
,  ||| S:462 E:464 ||| ,
exposed  ||| S:464 E:472 ||| VBN
to  ||| S:472 E:475 ||| TO
low  ||| S:475 E:479 ||| JJ
DON  ||| S:479 E:483 ||| NN
doses  ||| S:483 E:489 ||| NNS
without  ||| S:489 E:497 ||| IN
developing  ||| S:497 E:508 ||| VBG
acute  ||| S:508 E:514 ||| JJ
symptoms ||| S:514 E:522 ||| NNS
.  ||| S:522 E:524 ||| .
The  ||| S:524 E:528 ||| DT
adverse  ||| S:528 E:536 ||| JJ
effect  ||| S:536 E:543 ||| NN
of  ||| S:543 E:546 ||| IN
chronically  ||| S:546 E:558 ||| RB
consumed  ||| S:558 E:567 ||| VBN
low  ||| S:567 E:571 ||| JJ
DON  ||| S:571 E:575 ||| NN
doses  ||| S:575 E:581 ||| NNS
can  ||| S:581 E:585 ||| MD
not  ||| S:585 E:589 ||| RB
be  ||| S:589 E:592 ||| VB
totally  ||| S:592 E:600 ||| RB
excluded ||| S:600 E:608 ||| VBN
.  ||| S:608 E:610 ||| .
Using  ||| S:610 E:616 ||| VBG
a  ||| S:616 E:618 ||| DT
mouse  ||| S:618 E:624 ||| NN
model ||| S:624 E:629 ||| NN
,  ||| S:629 E:631 ||| ,
we  ||| S:631 E:634 ||| PRP
evaluated  ||| S:634 E:644 ||| VBD
the  ||| S:644 E:648 ||| DT
impact  ||| S:648 E:655 ||| NN
on  ||| S:655 E:658 ||| IN
inflammatory  ||| S:658 E:671 ||| JJ
status  ||| S:671 E:678 ||| NN
of  ||| S:678 E:681 ||| IN
subchronic  ||| S:681 E:692 ||| JJ
administration  ||| S:692 E:707 ||| NN
of  ||| S:707 E:710 ||| IN
DON  ||| S:710 E:714 ||| NNP
given  ||| S:714 E:720 ||| VBN
at  ||| S:720 E:723 ||| IN
doses  ||| S:723 E:729 ||| JJ
comparable  ||| S:729 E:740 ||| JJ
to  ||| S:740 E:743 ||| TO
the  ||| S:743 E:747 ||| DT
daily  ||| S:747 E:753 ||| JJ
human  ||| S:753 E:759 ||| JJ
consumption ||| S:759 E:770 ||| NN
.  ||| S:770 E:772 ||| .
The  ||| S:772 E:776 ||| DT
inflammatory  ||| S:776 E:789 ||| JJ
status  ||| S:789 E:796 ||| NN
was  ||| S:796 E:800 ||| VBD
evaluated  ||| S:800 E:810 ||| VBN
in  ||| S:810 E:813 ||| IN
mice  ||| S:813 E:818 ||| NNS
receiving  ||| S:818 E:828 ||| VBG
1 ||| S:828 E:829 ||| CD
,  ||| S:829 E:831 ||| ,
2.5  ||| S:831 E:835 ||| CD
or  ||| S:835 E:838 ||| CC
25μg ||| S:838 E:842 ||| CD
/ ||| S:842 E:843 ||| CD
kg  ||| S:843 E:846 ||| CD
bw ||| S:846 E:848 ||| CD
/ ||| S:848 E:849 ||| CD
day  ||| S:849 E:853 ||| NN
DON  ||| S:853 E:857 ||| NN
during  ||| S:857 E:864 ||| IN
a  ||| S:864 E:866 ||| DT
10  ||| S:866 E:869 ||| CD
or  ||| S:869 E:872 ||| CC
30  ||| S:872 E:875 ||| CD
days  ||| S:875 E:880 ||| NNS
period ||| S:880 E:886 ||| NN
.  ||| S:886 E:888 ||| .
The  ||| S:888 E:892 ||| DT
systemic  ||| S:892 E:901 ||| JJ
interleukin-1  ||| S:901 E:915 ||| CD
beta  ||| S:915 E:920 ||| NN
( ||| S:920 E:921 ||| -LRB-
IL-1β ||| S:921 E:926 ||| NNP
)  ||| S:926 E:928 ||| -RRB-
concentrations  ||| S:928 E:943 ||| NNS
were  ||| S:943 E:948 ||| VBD
evaluated  ||| S:948 E:958 ||| VBN
by  ||| S:958 E:961 ||| IN
Elisa  ||| S:961 E:967 ||| NNP
and  ||| S:967 E:971 ||| CC
inflammatory  ||| S:971 E:984 ||| JJ
biomarker  ||| S:984 E:994 ||| JJ
mRNA  ||| S:994 E:999 ||| JJ
expressions  ||| S:999 E:1011 ||| NNS
were  ||| S:1011 E:1016 ||| VBD
quantified  ||| S:1016 E:1027 ||| VBN
by  ||| S:1027 E:1030 ||| IN
qPCR  ||| S:1030 E:1035 ||| JJ
within  ||| S:1035 E:1042 ||| IN
brain  ||| S:1042 E:1048 ||| NN
structures  ||| S:1048 E:1059 ||| NNS
and  ||| S:1059 E:1063 ||| CC
peripheral  ||| S:1063 E:1074 ||| JJ
organs ||| S:1074 E:1080 ||| NNS
.  ||| S:1080 E:1082 ||| .
While  ||| S:1082 E:1088 ||| IN
DON  ||| S:1088 E:1092 ||| NNP
intake  ||| S:1092 E:1099 ||| VBD
failed  ||| S:1099 E:1106 ||| VBN
to  ||| S:1106 E:1109 ||| TO
modify  ||| S:1109 E:1116 ||| VB
physiological  ||| S:1116 E:1130 ||| JJ
markers ||| S:1130 E:1137 ||| NN
,  ||| S:1137 E:1139 ||| ,
we  ||| S:1139 E:1142 ||| PRP
observed  ||| S:1142 E:1151 ||| VBD
a  ||| S:1151 E:1153 ||| DT
systemic  ||| S:1153 E:1162 ||| JJ
IL-1β  ||| S:1162 E:1168 ||| CD
increase  ||| S:1168 E:1177 ||| NN
and  ||| S:1177 E:1181 ||| CC
a  ||| S:1181 E:1183 ||| DT
modulation  ||| S:1183 E:1194 ||| NN
of  ||| S:1194 E:1197 ||| IN
pro-inflammatory  ||| S:1197 E:1214 ||| JJ
gene  ||| S:1214 E:1219 ||| NN
expression  ||| S:1219 E:1230 ||| NN
in  ||| S:1230 E:1233 ||| IN
brain  ||| S:1233 E:1239 ||| NN
structures ||| S:1239 E:1249 ||| NNS
,  ||| S:1249 E:1251 ||| ,
liver ||| S:1251 E:1256 ||| NN
,  ||| S:1256 E:1258 ||| ,
duodenum  ||| S:1258 E:1267 ||| NN
and  ||| S:1267 E:1271 ||| CC
adipose  ||| S:1271 E:1279 ||| JJ
tissue ||| S:1279 E:1285 ||| NN
.  ||| S:1285 E:1287 ||| .
We  ||| S:1287 E:1290 ||| PRP
bring  ||| S:1290 E:1296 ||| VBP
here  ||| S:1296 E:1301 ||| RB
the  ||| S:1301 E:1305 ||| DT
first  ||| S:1305 E:1311 ||| JJ
evidence  ||| S:1311 E:1320 ||| NN
that  ||| S:1320 E:1325 ||| IN
subchronic  ||| S:1325 E:1336 ||| FW
DON  ||| S:1336 E:1340 ||| FW
intake ||| S:1340 E:1346 ||| FW
,  ||| S:1346 E:1348 ||| ,
at  ||| S:1348 E:1351 ||| IN
doses  ||| S:1351 E:1357 ||| NNS
that  ||| S:1357 E:1362 ||| WDT
match  ||| S:1362 E:1368 ||| VBP
daily  ||| S:1368 E:1374 ||| RB
human  ||| S:1374 E:1380 ||| JJ
intake ||| S:1380 E:1386 ||| NN
,  ||| S:1386 E:1388 ||| ,
induces ||| S:1388 E:1395 ||| VBZ
,  ||| S:1395 E:1397 ||| ,
in  ||| S:1397 E:1400 ||| IN
a  ||| S:1400 E:1402 ||| DT
murine  ||| S:1402 E:1409 ||| JJ
model ||| S:1409 E:1414 ||| NN
,  ||| S:1414 E:1416 ||| ,
a  ||| S:1416 E:1418 ||| DT
central  ||| S:1418 E:1426 ||| JJ
and  ||| S:1426 E:1430 ||| CC
peripheral  ||| S:1430 E:1441 ||| JJ
low  ||| S:1441 E:1445 ||| JJ
grade  ||| S:1445 E:1451 ||| NN
inflammation ||| S:1451 E:1463 ||| NN
.  ||| S:1463 E:1465 ||| .
